Cytori Therapeutics, Inc. (NASDAQ: CYTX) represents a unique investment opportunity in both healthcare and regenerative medicine. Broad global access to regenerative medicine has been constrained by a limited availability of stem and regenerative cells. Cytori’s team of biologists and engineers have pushed scientific boundaries to overcome the limitation of cell access and allow affordable, real-time access to a patient’s own stem and regenerative cells for a potentially unlimited number of medical conditions.
To further this end, we have developed the Celution® System, which takes a patient’s own liposuctioned adipose (fat) tissue and separates out the rich concentration of stem and regenerative cells that resides naturally within this tissue. This process is intended to take place primarily at the bedside so that the cells can be re-delivered during the same surgical procedure or preserved for future use.
It is our goal to have a Celution® System in every major hospital and in thousands of specialty medical clinics around the world. Once installed, each device generates recurring revenue from sales of single-use components, a proprietary enzyme solution, and related surgical devices and instrumentation required for each procedure.